<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468285</url>
  </required_header>
  <id_info>
    <org_study_id>S108.4.104</org_study_id>
    <nct_id>NCT01468285</nct_id>
  </id_info>
  <brief_title>The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow</brief_title>
  <acronym>CBF</acronym>
  <official_title>A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effect of Betahistine on Cerebral Blood Flow and Gait in Subjects at Risk of Falling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This
      placebo-controlled pharmacodynamic treatment study will primarily explore the effect of
      betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a
      patient population with MRI evidence of cerebrovascular compromise. Also it will be measured
      if CBF changes correlate with gait and cognitive changes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral Blood Flow (CBF)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To explore the sustained effect of betahistine on the cerebral blood flow (CBF) in the whole brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional Cerebral Blood Flow (rCBF)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To explore the sustained effect of betahistine on the regional cerebral blood flow (rCBF) in pre-determined regions of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Gait or Balance Disorder Problems</condition>
  <arm_group>
    <arm_group_label>Treatment arm 1: betahistine dihydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 2: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betahistine dihydrochloride</intervention_name>
    <description>betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment</description>
    <arm_group_label>Treatment arm 1: betahistine dihydrochloride</arm_group_label>
    <other_name>AgisercÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets b.i.d., six weeks treatment</description>
    <arm_group_label>Treatment arm 2: placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with gait or balance disorder problems

          2. Male and female subjects aged on 40 years and above.

          3. Absence of known contraindications for betahistine treatment.

          4. Currently not on betahistine (of any formulation) treatment for at least 45 days prior
             to inclusion in the study.

          5. Subject consuming caffeinated or alcoholic beverages should have stable consumption
             throughout the study period.

        Exclusion Criteria:

          1. History of discontinuation of betahistine treatment (of any formulation) in the past
             due to lack of efficacy or side effects.

          2. Subjects treated with antihistamines and monoamine oxidase (MAO) inhibitors 30 days
             prior to inclusion in the study.

          3. Subjects with hypersensitivity to the active substance or to any of the excipients of
             the drug.

          4. Phaeochromocytoma

          5. Porphyria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Kazei, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63545</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63544</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interventional,placebo controlled</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betahistine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

